US stent billing at Medicare still under audit
This article was originally published in Clinica
Executive Summary
US auditors say they are continuing to investigate whether hospitals and physicians are appropriately billing Medicare for coronary stenting procedures. They intend to release their findings in fiscal year 2005, which began on October 1. The US inspector general (IG) assigned to the Health and Human Services department first disclosed plans for the study in October 2003, with a tentative release date sometime in fiscal 2004. But the IG's recently released 2005 "workplan" now sets the timetable for release in this fiscal year. A portion of the investigation looks at whether multiple procedures performed during a single visit to the cath lab should be billed as a single procedure. Another pending study looks at whether hospitals are mistakenly billing Medicare for laboratory services performed for patients with renal disease. Medicare pays a composite rate for dialysis that is supposed to include laboratory services, the IG's office said. The study is overdue. It was supposed to be released in 2004. Also ahead this year is a report on payments for nerve conduction studies - electrodiagnostic tests of the integrity of the peripheral nerves. Medicare-allowed amounts for these studies went from $136m in 2000 to $186m in 2001 - or a 37% increase.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.